MedTrace Logo

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

NCT07521007 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 456

Last updated 2026-04-09

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

Conditions

Interventions

DRUG

YN001/Placebo 40mg

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

DRUG

YN001/Placebo 20mg

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

DRUG

YN001/Placebo 0mg

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Sponsors & Collaborators

  • The TIMI Study Group

    collaborator OTHER

  • Beijing Inno Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ying Chen, PhD · Beijing Inno Medicine Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-07-31
Completion
2029-03-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07521007 on ClinicalTrials.gov